Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study)

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Young, Elisa J ^a   Tabrizi, Sepehr N ^a,e   Brotherton, Julia M L ^b,e   Wark, John D ^e   Pyman, Jan ^a   Saville, Marion ^b   Wrede, C D ^d   Jayasinghe, Yasmin ^d,e   Tan, Jeffrey ^d   Gertig, Dorota M ^b,e   Pitts, Marian ^c   Garland, Suzanne M ^a,e  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b VCS Inc   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

^d Dept of Oncology/Dysplasia RWH ^*  (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cervical cancer; CIN3; Human papillomavirus; LCM; Pap smears

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; ATTITUDE TO HEALTH; AUSTRALIA; CANCER IMMUNIZATION; COHORT ANALYSIS; CROSS PROTECTION; DNA DETERMINATION; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; INTERNET; KNOWLEDGE; MEDICAL RECORD; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PREVALENCE; PREVENTIVE MEDICINE; RISK REDUCTION; SEXUAL BEHAVIOR; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; VIRUS DETECTION; ADOLESCENT; CERVICAL INTRAEPITHELIAL NEOPLASIA; GENETICS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AUSTRALIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84879061537     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-296     Document Type: Article

References (45)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917. 10.1002/ijc.25516, 21351269.
2. Welfare AIoHa Cervical Screening in Australia 2009-2010, Cancer series no. 67 2012, Canberra: AIHW, Welfare AIoHa.
3. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006, 367(9509):489-498. 10.1016/S0140-6736(06)68181-6, 16473126.
4. Rogstad KE. The psychological impact of abnormal cytology and colposcopy. BJOG 2002, 109(4):364-368. 10.1111/j.1471-0528.2002.99023.x, 12013155.
5. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004, 291(17):2100-2106. 10.1001/jama.291.17.2100, 15126438.
6. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943. 10.1056/NEJMoa061760, 17494926.
7. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007, 369(9574):1693-1702. 10.1016/S0140-6736(07)60777-6, 17512854.
8. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl 5):F123-F138.
9. Tabrizi S, Brotherton J, Kaldor JM, Skinner R, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012, in press.
10. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88(1):63-73. 10.1038/sj.bjc.6600688, 2376782, 12556961.
11. Brotherton JM. How much cervical cancer in Australia is vaccine preventable? A meta-analysis. Vaccine 2008, 26(2):250-256. 10.1016/j.vaccine.2007.10.057, 18068276.
12. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006, 24(Suppl 3):S3/26-34.
13. De Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7(7):453-459. 10.1016/S1473-3099(07)70158-5, 17597569.
14. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. International journal of cancer Journal international du cancer 2007, 121(3):621-632. 10.1002/ijc.22527, 17405118.
15. Gertig DM, Brotherton JM, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011, 8(2):171-178. 10.1071/SH10001, 21592430.
16. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377(9783):2085-2092. 10.1016/S0140-6736(11)60551-5, 21684381.
17. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87(7):544-547. 10.1136/sextrans-2011-050234, 21970896.
18. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11(1):39-44. 10.1016/S1473-3099(10)70225-5, 21067976.
19. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009, 85(7):499-502. 10.1136/sti.2009.037788, 19837728.
20. Brotherton JM, Kaldor JM, Garland SM. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. Sex Health 2010, 7(3):310-319. 10.1071/SH09137, 20719220.
21. Garland SM, Brotherton JM, Condon JR, McIntyre PB, Stevens MP, Smith DW, Tabrizi SN. Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med 2011, 9:104. 10.1186/1741-7015-9-104, 3182900, 21910918.
22. Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004, 23(5):569-578. 10.1016/j.vaccine.2004.07.046, 15630792.
23. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009, 113(1):18-25. 2694845, 19104355.
24. Fenner Y, Garland SM, Moore EE, Jayasinghe Y, Fletcher A, Tabrizi SN, Gunasekaran B, Wark JD. Web-based recruiting for health research using a social networking site: an exploratory study. J Med Internet Res 2012, 14(1):e20. 10.2196/jmir.1978, 3374531, 22297093.
25. Bhatla N, Dar L, Patro AR, Kumar P, Kriplani A, Gulati A, Iyer VK, Mathur SR, Sreenivas V, Shah KV, et al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?. Cancer Epidemiol 2009, 33(6):446-450. 10.1016/j.canep.2009.10.013, 19931499.
26. Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, Howard M, Chong S, Daya D, Chapman W, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. Cmaj 2000, 163(5):513-518. 80457, 11006761.
27. Winer RL, Feng Q, Hughes JP, Yu M, Kiviat NB, O'Reilly S, Koutsky LA. Concordance of self-collected and clinician-collected swab samples for detecting human papillomavirus DNA in women 18 to 32 years of age. Sex Transm Dis 2007, 34(6):371-377.
28. Wright TC, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000, 283(1):81-86. 10.1001/jama.283.1.81, 10632284.
29. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38(1):357-361. 88724, 10618116.
30. Layton-Henry J, Scurry J, Planner R, Allen D, Sykes P, Garland S, Borg A, Tabrizi S. Cervical adenoid basal carcinoma, five cases and literature review. Int J Gynecol Cancer 1996, 6(3):193-199.
31. Stevens MP, Garland SM, Tabrizi SN. Human papillomavirus genotyping using a modified linear array detection protocol. J Virol Methods 2006, 135(1):124-126. 10.1016/j.jviromet.2006.02.007, 16564098.
32. Stevens MP, Garland SM, Tabrizi SN. Validation of an automated detection platform for use with the roche linear array human papillomavirus genotyping test. J Clin Microbiol 2008, 46(11):3813-3816. 10.1128/JCM.01169-08, 2576620, 18784316.
33. Tabrizi SN, Stevens M, Chen S, Rudland E, Kornegay JR, Garland SM. Evaluation of a modified reverse line blot assay for detection and typing of human papillomavirus. Am J Clin Pathol 2005, 123(6):896-899. 10.1309/MPERNJ0G62RECHCQ, 15899782.
34. Stevens MP, Garland SM, Tabrizi SN. Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J Virol Methods 2008, 147(2):290-296. 10.1016/j.jviromet.2007.09.018, 17996311.
35. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. Cmaj 2007, 177(5):469-479. 1950172, 17671238.
36. National Cervical Screening Program Renewal http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/ncsp-renewal, National Cervical Screening Program Renewal.
37. Gunasekaran B, Jayasinghe Y, Fenner Y, Moore EE, Wark JD, Fletcher A, Tabrizi SN, Garland SM. Knowledge of human papillomavirus and cervical cancer among young women recruited using a social networking site. Sex Transm Infect 2012, 0:1-3.
38. Australian Institute of Health and Welfare Cervical screening in Australia 2008-2009. Cancer Series. vol. no. 61 2011, Canberra: Australian Institute of Health and Welfare, Australian Institute of Health and Welfare.
39. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011, 13:100-110.
40. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Lebacq M, van der Most R, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011, 7(12):1359-1373. 10.4161/hv.7.12.18282, 3338933, 22048172.
41. Munoz N, Bosch FX, Castellsague X, Diaz M, De Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 111(2):278-285. 10.1002/ijc.20244, 15197783.
42. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(3):621-632. 10.1002/ijc.22527, 17405118.
43. Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 2005, 32(Suppl 1):S1-S6.
44. Chan SY, Delius H, Halpern AL, Bernard HU. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol 1995, 69(5):3074-3083. 189008, 7707535.
45. Halpern AL. Comparison of papillomavirus and immunodeficiency virus evolutionary patterns in the context of a papillomavirus vaccine. J Clin Virol 2000, 19(1-2):43-56.